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Summary Photodynamic therapy (PDT) using Photofrin was used in combination with a hypoxic toxin
(mitomycin C, MMC) to treat four patients with recurrent skin metastasis of a mammary carcinoma. In
precinical experiments an additive effect was found for the combination of MMC and PDT for treating
subcutaneous RIFI tumours in mice. When interstitial PDT was combined with a low dose of MMC
(administered 15 min before illumination), the Photofrin dose or light dose could be reduced by a factor of 2 in
order to obtain equivalent cure rate or growth delay. In the clinical pilot study, a low dose of Photfrin
(0.75 mg kg-') was used for PDT alone (superficial illumination) or combined with low-dose MMC
(5 mg m-2). Different tumour areas were illuminated with or without a preceding infusion of MMC. Both
tumour response and skin photosensitivity were scored. After 8-12 weeks of treatment, tumour cure could be
achieved by administering light doses > 150 J cm-2 for PDT alone and similar effects were obtained when light
doses of 75-87.5 J cm-2 were given after infusion with MMC. In all cases necrotic tissue of both tumour and
surrounding skin was observed, which lasted for a mean of 5 months (range 2-20 months). Skin phototoxicity,
tested by using a standardised illumination of skin patches on the back, lasted maximally 3 weeks. Three main
conclusions could be drawn from these studies: (1) The enhanced effects of the combination of PDT and MMC
observed in mouse tumours can be extrapolated to patients with mammary skin metastasis. (2) The
combination of PDT and hypoxic toxins facilitates treatment by permitting lower doses ofphotosensitiser to be
used (thereby reducing skin phototoxicity) or lower light doses (thereby reducing illumination times and
allowing the possibility to treat larger tumour areas). (3) Restoration of skin after PDT in previously treated
tumour areas (chemotherapy, radiation therapy and surgery) is very slow.
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Photodynamic therapy is now becoming a more accepted
form of treatment for small superficial tumours. Its major
advantage is the relatively selective treatment of tumours with
preservation of the surrounding normal tissue. Preferential
retention of the photosensitiser by the tumour tissue and
selective illumination are the cornerstones in this treatment.
To obtain total tumour eradication, the light used to excite
the photosensitiser must penetrate the full depth of the
tumour tissue (Ben Hur et al., 1987) and sufficient
photosensitiser and oxygen must be available for the
formation of highly reactive singlet oxygen. Direct tumour
cell kill may arise from this process but vasculature effects
will also lead to hypoxia. If the hypoxia is deep and long
lasting enough, additional tumour cells will be killed as a
consequence of this hypoxia (Henderson et al., 1985; Star et
al., 1986). Subcurative treatment, leading to recurrence of
tumour can therefore be the result of inadequate light
penetration, a lack of oxygen or low sensitiser dose. Tumour
tissue is often not optimally vascularised and areas of
hypoxia have been observed by many investigators, not
only in animal models but also in human tumour tissues. The
photochemical reaction itself will also consume oxygen and
this can lead to an oxygen deficit during prolonged
illumination, even when the vasculature is intact (Foster et
al., 1993). It is therefore believed that an important limitation
in successful PDT is the lack of oxygen. Several studies have
been directed to overcome this problem by techniques that
can replace or increase the oxygen content in the tumour, e.g.
addition of carbogen (Fingar et al., 1988) or by increasing
tumour blood flow (Foster et al., 1993; Cowled and Forbes,
1989). An alternative approach is to exploit the PDT-induced
hypoxia by the addition of a hypoxic toxin which will
specifically target cells at low oxygen tensions (Baas et al.,
1993; Bremner et al., 1990, 1992; Cho et al., 1992; Gonzalez
et al., 1986).
Breast cancer is the most common cancer in females in all
industrialised countries. Although the initial treatment of
breast cancer is very successful, many patients are at risk of
developing a recurrence in the course of their disease. Distant
metastasis will be found in approximately half of the patients
and 5-10% will suffer from local residual or recurrent
disease. Local recurrences are treated with various modalities,
such as surgery, hormonal or chemotherapy or radiation
therapy. In spite of these treatments, some patients will still
suffer from residual disease and complain initially of the
cosmetic changes. If left untreated, ulceration and pain will
become a serious risk. For these patients, photodynamic
therapy could be an alternative treatment and it has been
shown to be feasible by Kahn et al. (1993), Schuh et al.
(1987) and Sperduto et al. (1991).
The major side-effect of PDT using Photofrin is skin
phototoxicity since the injected photosensitiser is also
retained by the skin. Sensitivity for intense light can last
from 8 to 12 weeks after standard Photofrin doses of
2 mg kg-'. A reduction in the duration of skin phototoxicity
can be obtained by decreasing the photosensitiser dose
(Wilson et al., 1992). However, since the photochemical
process is then less efficient, illumination times have to be
increased (Kahn et al., 1993). For patients with multiple
lesions or large treatment areas, prolonged illumination times
are undesirable. A combination of a hypoxic toxin and PDT
could enable the use of a lower photosensitiser dose and/or
reduced illumination times. We therefore initiated a study to
determine the influence of a hypoxic toxin (mitomycin C) on
the photodynamic effect in tumours and normal tissue of
mice and a pilot study in patients with mammary skin
metastases. The tumour response and the duration of the skin
phototoxicity in patients was tested for a low dose of
Photofrin. The pharmacokinetic profile of a single injection
of mitomycin C was also measured.
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Materials and methods
Preclinical experiments
All experiments were carried out in accordance with protocols
approved by the local animal welfare committee and
conformed to national and international laws. C3H/Km
female mice (25-30 g) were inoculated with 1 x 105 RIF1
cells on the lower dorsum. Within 14 days most tumours had
grown to a size of 5-6 mm diameter and were used for
treatment. Tumour response was evaluated by measuring the
tumour three times aweekwith verniercallipers andcalculating
the time to increase by 2 mm inmean diameter from the time of
treatment (regrowth time). Cures were defined as no visible and
palpable tumour 90 days after treatment. Cures were excluded
from the analysis of mean regrowth times and were analysed
separately. Aminimum ofsixmice perdosegroup were treated.
Normal skin damage was assessed in female Balb/c mice
(21 -30 g at 14-30 weeks). The mice were anaesthetised with
intraperitoneally (i.p.) Nembutal (sodium-pentobarbital
60 mg kg-'; Abbot, The Netherlands) before hair on the
back was plucked (area of approximately 5 cm'). Photofrin
was injected i.p. in a dose of 10 mg kg-' and the skin was
illuminated superficially after 1 day. Skin response was
measured three times weekly using a visual scoring scale
[ranging from slight redness (grade 1), intense redness (grade
2), desquamation (grade 3) to scab formation (grade 4)] by
two independent observers (Baas et al., 1994). A minimum of
eight mice per group were treated.
Photosensitiser
Photofrin (QLT, Vancouver, Canada) was used in all
experiments. Vials containing dry powder (15 mg) were
diluted in 5% dextran to a concentration of 2 mg kg-'.
The drug was injected i.p. in a dose of 5 or 10 mg kg-' 24-
30 h before illumination. The mice were housed in a
darkened room for 2 weeks after injection of Photofrin.
Mitomycin C
MMC (2 mg vials, Kyowa, Japan) was dissolved in sterile
water to a concentration of 5 mg ml-'. The drug was
prepared directly before use and injected i.p. in a
concentration of 5 mg kg-' 15 min or 24 h before the start
of illumination. This drug concentration had been shown to
cause minimal acute toxicity (Baas et al., 1994).
Interstitial photodynamic tumour treatment
Laser light was obtained from an argon dye laser (Spectra
Physics model 171, San Jose, CA, USA) which pumped a dye
laser (Spectra Physics model 375) tuned at 628+3 nm. The
laser light was transported via polystyrene fibres with a 1-cm-
long terminal cylindrical diffusing tip (Baas et al., 1993). The
diffusing tip was inserted through the centre of the tumour.
To avoid hyperthermal effects, the light fluence rate was fixed
at 100 mW cm-'. The energy deposition varied from 100 to
400 J cm-'.
Superficial photodynamic treatment
Superficial illumination ofnormal skin ofmice was given by a
cold light lamp (type KL 1500, Scott, Mainz, Germany,
emission spectrum 300-700 nm) fitted with a 150 W halogen
lamp (Osram, The Netherlands). A fluence rate of
200 mW cm-2 was used to deliver energies of 0- 150 J cm-2
to skin patches of 2.5 cm2 in a maximum illumination time of
12.5 min as described previously (Baas et al., 1994). The
maximum skin temperature with thisfluence ratewas 41 -43°C.
Statistical analysis
Means and standard errors were calculated for tumour
regrowth times for each group. Cured tumours were
excluded from this analysis. Comparisons between groups
were by means of Breslow statistics stratified for the light
dose. This is a modified version of the Kruskal-Wallis (or
generalised Wilcoxon) test and allows cures to be incorpo-
rated in the analysis as sensored observations. A P-value of
<0.05 was considered significant. Cures were also analysed
separately by probit analysis to determine the light dose
giving a 50% cure rate (TCD50).
Clinical experiments
Patients entering this pilot study had to fulfil the following
criteria: a cytological/histological proof of the mammary
skin metastasis or a recent increase in tumour size; total
treatment surface should not exceed 100 cm2, ECOG
(Eastern Cooperative Oncology Group) performance score
<3; no concurrent chemotherapy, radiation or hormonal
therapy in the last 4 weeks before treatment; normal
haematology, liver and renal function; no previous
treatment with PDT or MMC; no porphyria. A written
informed consent was obtained from each patient and the
experiment was approved by the local medical ethical
committee.
Photosensitiser and mitomycin C
Photofrin was injected in a dose of 0.75 mg kg-'
intravenously. MMC (5 mg m-2) was given 20 min before
illumination in a slow push injection. Patient serum was
obtained from the contralateral cubital vein after injection.
MMC concentration was determined by high-perform-
ance liquid chromatography (HPLC) (Den Hartigh et al.,
1980).
Photodynamic therapy
Skin metastases with a diameter of <3.0 cm and estimated
thickness of <0.5 cm were considered suitable for
illumination. Laser light (630 nm) obtained from the argon
dye laser was transmitted via a quartz fibre with a
microlens tip (Quadra Logic Technology, Pearl River,
NY, USA). The patient was treated in a supine position
with a beam spot of 7 cm2 (diameter 3 cm) aimed at the
tumour area at a mean distance of 25-30 cm. The fluence
rate at the tumour surface was calculated to be
150 mW cm-2. Energies of 125-200 J cm-2 were adminis-
tered in 15-25 min for the treatment with Photofrin alone.
On day 1 after injection of the photosensitiser a test dose
of 150 J cm-2 was given to a tumour area and on day 2
other tumour areas were treated with the same dose if a
discoloration had occurred in the treated area or with an
increased light dose of 175 or 200 J cm-2 if no significant
changes had occurred. On day 3, MMC was injected as
described above. Twenty and 40 min after infusion of the
MMC new tumour areas were treated with half the light
dose (e.g. 75 or 87.5 J cm-2). On day 3 or 4, additional
treatments were given to the remaining tumour areas using
a light dose of 150 J cm-2 without MMC. Evaluation of
the response was performed every 3 weeks for the first 12
weeks and then every 4 months by visual inspection and
photography. If possible cytological evaluation was also
performed.
Skin phototoxicity
The extent of skin phototoxicity induced by this low dose of
Photofrin was determined using the method described by
Baas et al. (1995). Skin patches of 2.5 cm2 on the normal skin
of the back were illuminated weekly after administration of
the photosensitiser. The energy applied to the skin patches
varied from 10-50 J cm-2 (fluence rate 150 mW cm-2).
After 1 h the induced erythema was measured using a
Minolta Chroma Meter (type CR-200, Minolta Camera,
Osaka, Japan) and by visual scoring.Results
Preclinical results
Previous published results had demonstrated that Photofrin-
mediated PDT was enhanced by MMC given before
illumination when high doses of both photosensitiser
(10 mg kg-') and MMC (5 mg kg-') were given (Baas et
al., 1994). New studies demonstrate that the enhanced effect
is still seen using lower doses of either photosensitiser
(5 mg kg-') or MMC (2.5 mg kg-'). All the combined
treatments gave longer tumour regrowth times (Table I)
and more cures (Table II) than PDT alone or MMC alone
(P<0.0001). Tumour regrowth times decreased significantly
(P<0.0001) when PDT was given with low doses of
Photofrin (5 mg kg-') instead of the standard Photofrin
dose of 10 mg kg-'. The maximum effect was obtained using
high doses of both drugs but the regrowth times and TCD50
values (light dose required for 50% tumour cure) for 2.5 and
S mg kg-' MMC with the high photosensitiser dose were not
significantly different.
The mouse skin phototoxicity scoring system as described
by Baas et al. (1995) was used to evaluate the combination of
Photofrin (10 mg kg-', given 1 day before illumination) and
MMC (5 mg kg-', given 15 min before illumination). Using
the visible scoring system it was possible to obtain
reproducible profiles for skin damage. The mean skin
reactions for different light doses given 1 day after injection
of Photofrin with or without MMC are shown in Figure la.
A slight increase in mean skin reaction was observed when
PDT was combined with MMC given 15 min before
illumination. A light dose of 75 J cm-2 in combination with
MMC produced as much skin damage as 90 J cm-2 PDT
alone. MMC given 24 h before illumination did not increase
skin reactions relative to PDT alone (data not shown). In
order to compare skin reactions quantitatively after PDT, a
light dose response curve was constructed for the incidence of
dry and moist desquamation. Only animals with at least 25%
of the illuminated area developing desquamation were scored
as 'responders'. Figure lb illustrates the results of these
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calculations. This analysis demonstrated no significant
difference in the incidence of desquamation response
between PDT alone or in combination with MMC (light
doses of 49.0+6.3 and 57.0+7.9 J cm-2 gave a response in
50% of the mice).
Clinical results
Four patients were entered in the pilot study in a 2 year
period. The patient characteristics are presented in Table III.
All had previous treatments for their recurrent mammary
metastases. The major complaints at time of PDT were
progression of the tumours and the resultant cosmetic
appearance. All patients were treated according to the
protocol, and three patients fulfilled all inclusion criteria,
including positive cytology. The fourth patient experienced
progression of the lesions but the repeated cytological
examination was negative (insufficient material).
In all patients a predictable course of tumour reaction was
observed: no direct change of the tumour during the light
treatment but a brown-bluish discolouration which developed
after 24 h (Figure 2). Over the next 10 days the lesion turned
into a dry black scab which was present for at least 8 weeks.
Areas treated with light doses of > 150 J cm-2 (PDT alone)
or some areas treated with 75-88 J cm-2 in combination
with MMC, had scabs lasting 8-20 months (Figure 3). In
most treated tumour areas, normal skin reappeared after the
scab had fallen off. In patient 1, skin metastases were also
located on the back and treated according to the protocol.
The scabs resolved soonest in these illuminated areas with
perfect healing of the skin. In 3 of the 19 lesions treated an
exudative local infection developed, two could be treated
locally but one required a course of oral antibiotics. One
treatment session was complicated by a burning sensation
14 min after the start of the treatment (administered dose:
128 J cm-2). Further treatment was delayed for 24 h and no
change occurred in the treated area. Further illumination
procedures were uneventful. One patient died 4 months after
treatment owing to newly diagnosed bone metastasis in the
Table I The effect of laser illumination and drugs on tumour regrowth times (days) in mice
Light dose (J cm-)
Treatment 0 100 200 300 400
MMC 4.1+0.2 -
(2.5 mg kg-)
MMC 5.8 0.5 --
(5 mg kg'l)
PDTa - 7.9+1.0 12.3+ 1.3 13.1+1.3 15.0+1.3
PDr +MMC - 15.0±1.3 13.9i1.3 14.3±1.3 24.5+ 2.2
(2.5 mg kg-')
PDTa+MMC - 20.8+1.3 27.7 ±6.7 27.3 ± 6.0 25.8+ 3.5
(5 mg kg-I)
PDT 4.8+0.4 11.5+0.9 16.0+0.9 16.5+ 1.0 16.0+0.8
PDTb+MMC - 20.7+2.3 23.1 +2.8 24.2+6.4
(2.5 mg kg-')
PDTb+MMC 8.5 +0.8 18.2+3.2 23.1 + 1.0 22.3+1.5 31.9+0.9
(5 mg kg-1)
a5 mg kg-1 Photofrin. blO mg kg-' Photofrin/previously published by Baas et al. (1994).
Table II The effect of PDT+ MMC on local tumour control in mice (number of cured tumours per dose group)
Light dose PDr+MMC PDP+MMC PD7b+MMC
(J cm-2) PD1 alone 2.5 mg kg-' 5 mg kg-' (5 mg kg-')
0 0/18 0/6 0/8 -
100 1/25 - 0/8 0/8
200 0/23 1/8 4/8 0/8
300 1/29 4/10 3/10 2/8
400 1/24 5/8 7/10 1/8
500 5/15 - -
-
TCD50 731+170 348+41 319+49 ND
alo mg kg-' Photofrin. b5 mg kg-1 Photofrin. ND, not determined.Photodynamic therapy by mitomycin C
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lumbar column leading to progressive paralysis. The three
other patients are still alive (>18 months), but all showed
progression of their disease, including new skin metastases or
distant (pleuritic) metastases requiring systemic chemother-
apeutic or advanced hormonal treatments.
In Table IV the responses to the different treatment
combinations are shown for all patients 8 weeks after
treatment. Thirteen tumour areas were treated with PDT
alone and seven in combination with MMC. Tumour control
could only be achieved by light doses of > 150 J cm-2 PDT
a
a)
o
0)
cJ
a1)
(10/11). The response to treatment with 50% light dose after
infusion of MMC was comparable to a full light dose with
PDT only. Although the majority of the tumour metastases
responded with a complete response (5/7), two partial
responses were observed. Evaluation of the tumour
responses after 1-2 years showed new skin metastases or
recurrences in the border of the illuminated area in all three
remaining patients. Of the 15 lesions treated in patients with
long survival (patients 1, 2 and 4) only five did not show
recurrences of tumour. A total of eight were treated with
Photofrin alone, and the distribution of long-term cures was
one treated with 150 J cm-2, two with 175 J cm-2 and one
with 200 J cm-2. Five tumour areas were treated in
combination with MMC and only one showed no evidence
of tumour recurrence (88 J cm-2).
Three patients had blood samples analysed for mitomycin
C concentration. Initially a high serum concentration was
measured which declined rapidly. The values of clearance of
MMC of patients 2, 3 and 4 are 11.2, 25.3 and 32.61 h-'.
Calculation of the t1/2 resulted in 15, 35 and 96 min which is
in accordance with the variation found for the half-life of
MMC in patients (Crooke and Bradner, 1976; Verweij and
Pinedo, 1990).
Normal skin response
The skin response to a standardised illumination with 10-
50 J cm-2 was assessed at various time intervals after
Time after treatment (days)
10c
In
0)
-
0-
0.
in
0) U)
cc
b
administration of Photofrin. The results for a light dose of
25 J cm-2 are presented in Figure 4. A marked skin reaction
was evident at 2-16 days but by 25-30 days there was no
remaining skin photosensitivitv. The duration of the skin
photosensitivity after 0.75 mg kg-' Photofrin was consider-
ably shorter than after a 'standard' dose of 2 mg kg-'
0
PDT alone /
PDT + MMC
0 25 50 75 100 125
Light dose (J cm-2)
Figure 1 (a) Mean skin reaction in mice as a function of time
after Photofrin-mediated PDT in combination with (open
symbols) without (closed symbols) MMC (Ol/O, 30Jcm- ; A,
75Jcm- ; V, 90Jcm-2). Each data point represents the
mean + s.e.m. from a group of eight mice. (b) Incidence of
responders after Photofrin-mediated-PDT as a function of the
light dose. Responders are defined as having a minimum of 25%
of the illuminated area exhibiting dry desquamation and/or scab
formation.
Figure 2 Patient tumour response 24h after illumination with
l50Jcm-2 and 2 days after injection of 0.75mgkg-1 Photofrin.
The treated area shows discoloration and slight swelling.
Table m Patient characteristics
Patient number
1 2 3 4
Age (years) 50 49 74 45
Weight (kg) 60 91 74 70
SA (m2) 1.7 2.1 1.6 1.8
Photofrin dose 50 68 45 50
(mg)
MMC dose (mg) 8.5 10.5 8 9
Previous treatment Surgery, HT RT, HT, CT Surgery Surgery, HT, CT,
RT
Complaints before Cosmetic Cosmetic Cosmetic Cosmetic
PDT Progression Progression Progression Progression
Pain
SA, surface area; HT, hormonal treatment; RT, radiotherapy; CT, chemotherapy.
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Photofrin (data derived from a lung cancer patient treated
with PDT, Baas et al., 1995). All patients were advised to
avoid direct sunlight for 2 weeks after injection and then
gradually expose their skin. No side-effects were experienced
by the patients and normal activity could be resumed within
2-3 weeks.
Discussion
Chronic tumour hypoxia, owing to pronounced PDT-induced
vascular damage, is considered to be one of the major
mechanisms whereby PDT kills tumour cells in vivo
(Henderson et al., 1985; Reed et al., 1988). Various
laboratory investigators have therefore explored the ap-
proach of combining bioreductive drugs with photodynamic
therapy in order to exploit the PDT-induced hypoxia and
enhance the tumoricidal effect of the bioreductive drug
(Evensen and Moan, 1988; Gonzalez et al., 1986; Winther
et al., 1988; Bremner et al., 1992; Baas et al., 1994; Van Geel
et al., 1995). In most cases an advantage was observed for the
combination therapy although exact timing of the adminis-
tration of the bioreductive drug appeared to be important
(Evensen and Moan, 1988; Winther et al., 1988).
In the present preclinical and clinical study we chose
MMC as the bioreductive drug to be combined with PDT
despite its relatively low oxic/hypoxic ratio of 2 to 3
(concentration of drug necessary to kill equal amounts of
tumour cells in aerobic conditions vs hypoxic conditions).
The reasons for this choice were that this drug is a well-
established clinical cytotoxic drug with limited or no side-
effects in a single administered dose of 5 mg m-2 and that
our previous preclinical experiments indicated that the
combination of MMC with PDT was effective.
The mouse tumour experiments described in this study
clearly show an enhanced effect of the combination of
Photofrin-mediated PDT and MMC. This effect was
observed both for a standard (high) dose of Photofrin and
MMC and for reduced doses of photosensitiser and MMC.
The skin phototoxicity in mice increased slightly for the
groups treated with both PDT and MMC in the higher light
doses when MMC was given 15 min before illumination.
Lower light doses did not show an increase in skin sensitivity
in the combination group. There was no enhanced skin
phototoxicity when MMC was given 24 h before illumina-
tion. The clinical importance of this enhanced skin
phototoxicity is therefore limited since it is of short duration.
To our knowledge this is the first clinical attempt to study
the combination of PDT with a bioreductive drug. From this
study of only four patients, no definitive conclusions can be
made. It appears, however, that superficial skin metastasis
can be treated with PDT alone or in combination with MMC
and lower light doses. The energy required to obtain a
complete response with PDT alone varied between
150 J cm-2 and 175 J cm-2 and is probably related to the
tumour volume and depth or, to a lesser extent, drug
distribution in the tumour. Large areas (>100 cm2) are
difficult to treat because adequate illumination with the
currently available lasers and fibres is too time-consuming.
One of the major problems encountered was the difficulty in
measuring the exact tumour thickness. Most lesions tended to
recur at later times (> 12 months), and we feel that the
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Figure 3 Two lesions in. one patient illuminated with 150
j CM2
after Photofrin-mediated PDT alone or with 75Jcm-2 in
combination with MMC injected 15min before illumination.
Days
Figure 4 Skin response in three patients injected with
0.75mgkg-1 (0) and in one patient injected with 2.Omgkg-
Photofrin (Cl) as a function of time from photosensitiser
injection. Illumination was standardised with 25Jcm-2 on
normal skin patches on the back at different days after the
single injection of Photofrin. The relative redness was measured
using a Minolta Chroma Meter 1 h after illumination.
Table IV Patient tumour response after PDT with/without MMC
Patient number
1 2 3 4
Light dose No No No No
(J cm-2) MMC MMC MMC MMC MMC MMC MMC MMC
75 PR PR CR
CR
88 PR 2xCR
CR
128 NC
150 NC 2xCR 2xCR
160 CR
175 4xCR
200 CR
CR, complete response at 12 weeks; PR, partial response; NC, no change.
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infiltrating nature of these tumours, together with the late
referral for the PDT treatment, accounts for these
disappointing long-term results.
All patients had been treated previously with chemother-
apy, radiation therapy and surgery, resulting in an abnormal
skin and probably also abnormal vascularisation. This may
account for the observed slow repair ofthe induced scabs and
infections since the metastasis of one patient located on the
back healed quickly without scarring. Superficial tumours,
like metastasis of mammary carcinoma or basal cell
carcinomas, have been previously treated by PDT with good
cosmetic results depending on the infiltration of the tumours
(Schuh et al., 1987; Wilson et al., 1992; Cairnduff et al.,
1994). Bandieramonte et al. (1984) treated similar patients
with PDT (using haematoporphyrin derivative as the
photosensitiser) and found more complete responders (21
out of 25) at 60 days for tumour lesions with an infiltration
of <4 mm than for lesions with infiltration of >4 mm (6 out
of 14). Although there was a follow-up of 4-16 months, no
information on local recurrences was given. Necrotic
ulceration was also observed, which necessitated specific
wound care but healed satisfactorily. Cairnduff et al. (1994)
treated five patients with metastatic breast carcinomas with
local application of 5-aminolaevulinic acid (5-ALA). Nodules
of 1 cm diameter treated with 150 J cm-2 showed a CR in 5
out of 15 lesions at 6 months. Our results are comparable
with these other published studies.
The addition of MMC given before illumination allowed
us to reduce the energy by a factor of approximately 2 and
still achieve the same tumour response. Of the seven tumour
areas treated with combined MMC and PDT only two failed
to achieve a complete response. These results seem to confirm
the enhanced effect of MMC and PDT we observed in the
mouse tumour model. All patients tolerated the combined
treatment without sequelae. Although we did not investigate
the effect of a single dose of MMC alone on mammary skin
metastases, it is not expected that this low single dose would
significantly influence the growth rate in the absence of PDT.
Timing of the injection of mitomycin C with respect to the
illumination appears to be important since the pharmacoki-
netic profile indicates that after 20 and 40 min only 60% and
25% of the drug remains in the serum, respectively. Whether
this reflects the actual activity is uncertain since the drug has
to diffuse through the tumour tissue and is cleared by the
liver. The calculated half-life in the three patients lies within
the expected range of 10-50 min according to the maximum
plasma concentration (Crooke and Bradner, 1976; Verweij
and Pinedo, 1990). Preclinical studies in other laboratories
are currently investigating whether the effect of MMC is
indeed due to a bioreductive effect or if other processes are
involved, such as enhanced uptake of the Photofrin in MMC-
treated cells or changes in cell cycle which renders the tumour
cells more sensitive for PDT (Ma et al., 1993).
With regard to the skin phototoxicity, patients showed an
increased sensitivity for the test doses of light immediately
after injection of low dose (0.75 mg kg-') Photofrin. This
lasted for 2-3 weeks as measured by the reflectance meter.
Normal outdoor activity could be resumed in the third week
after injection. These results are in clear contrast with the
normal skin photosensitivity encountered after the standard
advised dose of 2 mg kg-' of Photofrin, which lasts 4-12
weeks (Baas et al., 1995; Dougherty et al., 1990; Wilson et al.,
1986). The risk of treating patients with a low dose of
Photofrin could be the increased incidence of local tumour
recurrences owing to inadequate singlet oxygen production or
vessel damage. These recurrences of tumour metastasis were
indeed observed in our pilot study.
The conclusions that can be drawn from these studies are:
(1) The combination of a hypoxic toxin (MMC) and
Photofrin-mediated PDT increased the tumoricidal
effect in a mouse tumour model and in patients with
mammary skin metastasis. This allows a reduction of
light dose and/or photosensitiser dose.
(2) Skin photosensitivity was markedly less after low doses
of Photofrin than after the standard recommended dose
of 2 mg kg-'.
(3) Healing of the induced scabs was very slow in these
previously pretreated patients.
(4) Using this low sensitiser dose (0.75 mg kg-' Photofrin)
long-term cure was not routinely achieved. Infiltration
of the tumours beyond 5 mm or inadequate light
delivery at the tumour border could explain the limited
long-term effect. To overcome these failures, patients
should be referred for PDT at an earlier stage of the
disease or higher drug dose ofPhotofrin or more potent
photosensitisers should be used if the intention is to
treat curatively.
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